Lilian T Gien, Danielle M Enserro, Matthew S Block, Steven Waggoner, Linda R Duska, Andrea E Wahner-Hendrickson, Premal H Thaker, Floor Backes, Michael Kidd, Carolyn Y Muller, Paul A DiSilvestro, Allan Covens, David M Gershenson, Kathleen N Moore, Carol Aghajanian, Robert L Coleman
INTRODUCTION: Early reports of PD-1 inhibition in ovarian clear cell carcinomas (OCCC) demonstrate promising response. We evaluated the combination of pembrolizumab and IDO-1 inhibitor epacadostat in patients with recurrent OCCC. METHODS: This single arm, two-stage, phase 2 trial included those with measurable disease and 1-3 prior regimens. Patients received intravenous pembrolizumab 200 mg every 3 weeks and oral epacadostat 100 mg twice a day. Primary endpoint was overall response rate (ORR), secondary endpoints were toxicity, progression-free survival (PFS) and overall survival (OS)...
April 10, 2024: Gynecologic Oncology